ASCO may have been virtual this year because of the COVID-19 pandemic, but there were still some show-stopping moments, reports Richard Staines. This time of year oncologists from
Merck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations, offering patients a single-agent therapy opt
Merck & Co has joined with the non-profit scientific research organisation, the International AIDS Vaccine Initiative (IAVI), to develop a potential vaccine against the SARS-CoV-2 coron
The FDA has approved AstraZeneca and Merck & Co’s Lynparza (olaparib) in metastatic castration-resistant prostate cancer, just days after the regulator gave the nod for Clovis’ PARP-cla
AstraZeneca and Merck & Co’s Lynparza should be the standard therapy for a certain group of ovarian cancer patients according to US cancer experts reviewing long-term trial data.